Category: Featured

September 2, 2025

Peter J. McDonnell, M.D., Appointed to the Company’s Board of Directors

August 11, 2025

First FDA-Approved Treatment for MacTel Performed

Press Release – First Commercial Manufacturing, Shipment, and Surgical Procedure for ENCELTO (revakinagene taroretcel-lewy)

April 21, 2025

Neurotech Appoints Beth Marsh as Chief Commercial Officer

March 6, 2025

Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Adults with Idiopathic Macular Telangiectasia Type 2 (MacTel)

Press Release – Neurotech receives approval for ENCELTO (revakinagene taroretcel-lwey)

November 8, 2024

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) 

June 20, 2024

Neurotech Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) 

December 2, 2023

Rich Small, Chief Executive Officer, Presents a Company Update at the Retina Innovation Showcase at the Ophthalmology Innovation Summit (OIS) XIII

September 13, 2023

Alex Gorsky Appointed to Neurotech’s Board as Lead Director

January 10, 2023

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer

November 2, 2022

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel